Showing results (191-200 of 251) with videos related to
Sort By:
Pageof 26
Cancer Medicine|July 31, 2020
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION studyHidehito Horinouchi, Shinji Atagi, Satoshi Oizumi, et al.The Lancet. Oncology|June 6, 2020
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trialJun Sato, Miyako Satouchi, Shoichi Itoh, et al.Lung Cancer (Amsterdam, Netherlands)|December 21, 2024
Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort studyHidehito Horinouchi, Haruyasu Murakami, Hideyuki Harada, et al.Journal of Geriatric Oncology|July 13, 2024
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort studyNoboru Morikawa, Tateaki Naito, Meiko Morita, et al.Thoracic Cancer|October 24, 2023
Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancerMotoki Sekikawa, Haruyasu Murakami, Meiko Morita, et al.Lung Cancer (Amsterdam, Netherlands)|September 2, 2014
Identification of actionable mutations in malignant pleural mesotheliomaTakehito Shukuya, Masakuni Serizawa, Masaru Watanabe, et al.Thoracic Cancer|April 14, 2022
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancerNaoya Nishioka, Tateaki Naito, Taichi Miyawaki, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker AnalysisJames Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, et al.Lung Cancer (Amsterdam, Netherlands)|May 10, 2011
Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumorsKyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, et al.Lung Cancer (Amsterdam, Netherlands)|December 17, 2018
Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancerAkira Ono, Mitsuhiro Isaka, Masakuni Serizawa, et al.Pageof 26